Literature DB >> 16287070

Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein.

Ingo Melzner1, Marc A Weniger, Alexandra J Bucur, Silke Brüderlein, Karola Dorsch, Cornelia Hasel, Frank Leithäuser, Olga Ritz, Martin J S Dyer, Thomas F E Barth, Peter Möller.   

Abstract

Activity of Janus kinase 2 (JAK2) in the JAK2/STAT5 signaling pathway is critically controlled by suppressor of cytokine signaling-1 (SOCS-1). We have previously shown that SOCS-1 is biallelically mutated in the primary mediastinal B-cell lymphoma (PMBL) cell line MedB-1, resulting in impaired JAK2 degradation and sustained phospho-JAK2 action. SOCS-1 is frequently mutated in PMBL tumor primaries. Here, we report that the PMBL cell line Karpas1106P has a biallelic deletion of the SOCS-1 region on chromosome 16p13.13. By fluorescence in situ hybridization and microsatellite analysis, this deletion was narrowed down to a range of 650 kb to 1.48 Mb. Like MedB-1, Karpas1106P harbors gains of the JAK2 gene on chromosomal region 9p24 and elevated levels of JAK2 mRNA. Nevertheless, JAK2 protein was not increased but constitutively phosphorylated in Karpas1106P cells. In analogy to MedB-1 cells, Karpas1106P cells exhibited a retarded degradation of de novo synthesized JAK2 protein revealed by pulse/chase experiments. Therefore, we conclude that loss of SOCS-1 function either by mutation or by the complete deletion of the gene plays an important role in the dysregulation of JAK/STAT signaling in Karpas1106P and PMBL. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16287070     DOI: 10.1002/ijc.21485

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

Review 1.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

2.  MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.

Authors:  Christian Steidl; Sohrab P Shah; Bruce W Woolcock; Lixin Rui; Masahiro Kawahara; Pedro Farinha; Nathalie A Johnson; Yongjun Zhao; Adele Telenius; Susana Ben Neriah; Andrew McPherson; Barbara Meissner; Ujunwa C Okoye; Arjan Diepstra; Anke van den Berg; Mark Sun; Gillian Leung; Steven J Jones; Joseph M Connors; David G Huntsman; Kerry J Savage; Lisa M Rimsza; Douglas E Horsman; Louis M Staudt; Ulrich Steidl; Marco A Marra; Randy D Gascoyne
Journal:  Nature       Date:  2011-03-02       Impact factor: 49.962

3.  The molecular biology of diffuse large B-cell lymphoma.

Authors:  Mareike Frick; Bernd Dörken; Georg Lenz
Journal:  Ther Adv Hematol       Date:  2011-12

4.  TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis.

Authors:  Clara Dees; Sebastian Pötter; Yun Zhang; Christina Bergmann; Xiang Zhou; Markus Luber; Thomas Wohlfahrt; Emmanuel Karouzakis; Andreas Ramming; Kolja Gelse; Akihiko Yoshimura; Rudolf Jaenisch; Oliver Distler; Georg Schett; Jörg Hw Distler
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

5.  Integrated analysis of 10 lymphoma datasets identifies E2F8 as a key regulator in Burkitt's lymphoma and mantle cell lymphoma.

Authors:  An-Ping Yang; Leyna G Liu; Min-Min Chen; Fang Liu; Hua You; Lian Liu; Hua Yang; Yang Xun; Jing Liu; Rui-Xue Wang; David D Brand; Dahai Liu; Song Guo Zheng; Wen-Xing Li
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 6.  Beyond chemotherapy: new agents for targeted treatment of lymphoma.

Authors:  Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2010-12-14       Impact factor: 66.675

Review 7.  Targeting JAK kinase in solid tumors: emerging opportunities and challenges.

Authors:  M Buchert; C J Burns; M Ernst
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

8.  SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.

Authors:  Birgit Schif; Jochen K Lennerz; Christian W Kohler; Stefan Bentink; Markus Kreuz; Ingo Melzner; Olga Ritz; Lorenz Trümper; Markus Loeffler; Rainer Spang; Peter Möller
Journal:  Oncotarget       Date:  2013-01

Review 9.  JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.

Authors:  Karoline Gäbler; Iris Behrmann; Claude Haan
Journal:  JAKSTAT       Date:  2013-05-14

Review 10.  SOCS, inflammation, and cancer.

Authors:  Kyoko Inagaki-Ohara; Taisuke Kondo; Minako Ito; Akihiko Yoshimura
Journal:  JAKSTAT       Date:  2013-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.